As compound 4 was indicated to be the most potent inhibitor of NEP, the next step of the study was aimed at the investigation of whether the anti-osteosarcoma effect of this compound was associated with its NEP-inhibitory properties. The gene discussed is MME; the disease is osteosarcoma.